Bausch Health Companies (BHC) Stock Rating Reaffirmed by Cantor Fitzgerald
Bausch Health Companies (NYSE:BHC)‘s stock had its “buy” rating reiterated by analysts at Cantor Fitzgerald in a research report issued on Wednesday. They currently have a $32.00 price target on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 35.94% from the stock’s current price.
The analysts wrote, “We rate BHC as 12-month price target of $32. A greater appreciation for BHC’s solid execution and future growth prospects under the new management team should drive upwards earnings revisions in 2019+, multiple expansion, and BHC shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $32.””
BHC has been the subject of a number of other research reports. ValuEngine lowered shares of Bausch Health Companies from a “hold” rating to a “sell” rating in a report on Friday, September 7th. Piper Jaffray Companies set a $16.00 target price on shares of Bausch Health Companies and gave the stock a “sell” rating in a report on Tuesday, August 7th. Wells Fargo & Co reissued a “sell” rating on shares of Bausch Health Companies in a report on Monday, August 6th. Mizuho reissued a “buy” rating and issued a $31.00 price target on shares of Bausch Health Companies in a report on Tuesday, August 7th. Finally, Royal Bank of Canada boosted their price target on shares of Bausch Health Companies from $25.00 to $26.00 and gave the company a “hold” rating in a report on Wednesday, August 8th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $25.38.
Bausch Health Companies (NYSE:BHC) last released its earnings results on Tuesday, August 7th. The company reported $0.93 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.12. Bausch Health Companies had a negative net margin of 20.60% and a positive return on equity of 27.83%. The firm had revenue of $2.13 billion during the quarter, compared to analyst estimates of $2.05 billion. equities analysts expect that Bausch Health Companies will post 3.46 EPS for the current year.
Several hedge funds have recently made changes to their positions in BHC. Private Management Group Inc. acquired a new position in shares of Bausch Health Companies in the 2nd quarter valued at $28,474,000. Tobam acquired a new position in shares of Bausch Health Companies in the 2nd quarter valued at $13,886,000. Van ECK Associates Corp acquired a new position in shares of Bausch Health Companies in the 2nd quarter valued at $11,494,000. Marshall Wace LLP acquired a new position in shares of Bausch Health Companies in the 2nd quarter valued at $2,974,000. Finally, Point View Wealth Management Inc. acquired a new position in shares of Bausch Health Companies in the 2nd quarter valued at $1,132,000. 44.66% of the stock is owned by institutional investors.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Further Reading: Market Capitalization and Individual Investors
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.